鈴木 利貴央

Suzuki Rikio

  • 准教授
  • 学位:博士(医学)

基本情報

所属

  • Undergraduate School of Global Studies
  • Undergraduate School of Medicine / Faculty of Medicine

詳細情報

研究分野

  • Life sciences Hematology and oncology Multiple myeloma

受賞

  • 2013 ASH Abstract Achievement Award

論文

Coexistence of monomorphic epitheliotropic intestinal T-cell lymphoma of the jejunum and bilateral adrenal pheochromocytomas: A case report

Cord blood versus bone marrow/peripheral blood stem cell transplantation under reduced-intensity conditioning in high-risk acute myeloid leukemia and myelodysplastic syndromes.

Efficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: a case report of elranatamab and a literature review

Successful Treatment of Chronic Active Epstein-Barr Virus Infection Complicated by Cardiomyopathy in an Adult Patient.

ALK-negative anaplastic large cell lymphoma with TP53 mutation developing during the administration of baricitinib for atopic dermatitis - A case report.

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma

Liposome-encapsulated progesterone efficiently suppresses B-lineage cell proliferation.

Acute myeloid leukemia with a ZMYND11::MBTD1 fusion gene following chemotherapy and radiotherapy for breast cancer: A case report.

[Disseminated toxoplasmosis after cord blood transplantation diagnosed at autopsy].

Association of CDKN2A/2B deletion with relapse after hematopoietic stem cell transplantation for acute lymphoblastic leukemia.

Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.

Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma.

Risk factors for lower respiratory tract disease and outcomes in allogeneic hematopoietic stem cell transplantation recipients with influenza virus infection.

Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies.

Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan.

Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma.

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells.

Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Expression of activated integrin β7 in multiple myeloma patients.

共同研究・競争的資金等の研究課題

Development of a novel minimally invasive treatment for refractory and therapy-resistant hematological malignancies using food extracts.

Development of less invasive treatment for central nervous system invasion of refractory hematologic malignancies.

Elucidation and overcoming of drug resistance mechanism mediated by semaphorin 3A signal in multiple myeloma

ResearchMapへ移動します

Contact Us

Inquiries about coverage

Public Affairs Division Public Affairs and Communications Department

Tel. 0463-63-4670(direct dialing)